Affiliation:
1. Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, Italy
2. Dermatology Unit, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy
Abstract
Psoriasis can have a significant impact on quality of life and productivity, especially with increased severity. However, there is limited evidence on biologics’ efficacy in highly severe cases compared to moderate-to-severe ones. This study aimed to evaluate the effectiveness and safety of novel biological therapies in very severe psoriasis. We conducted a retrospective analysis on patients ≥ 18 years old affected by very severe psoriasis who had received a biological agent for at least 16 weeks. We used PASI to assess disease severity and effectiveness at weeks 16, 52, 104, and 156. Safety was evaluated by tracking treatment discontinuation rates and adverse events. This study included 29 males and 11 females, with a mean age of 55.80 years (SD 13.82). Cardiometabolic diseases were the most common comorbidities (25.00%). Twenty-eight (70.00%) patients had psoriasis involvement in at least one difficult-to-treat area. All patients completed 16 weeks of treatment. The mean PASI was 31.60 (SD 2.57) at baseline, 3.48 (SD 4.13) at week 16, 0.58 (SD 1.70) at week 52, 0.77 (SD 1.66) at week 104, and 1.29 (SD 2.12) at week 156. PASI90 and 100 were achieved by 52.50% and 30.00% of patients at week 16, by 96.15% and 80.77% at week 52, by 93.33% and 66.67% at week 104, and by 85.71% and 42.86% at week 156. PASIs ≤ 2 were achieved by 50.00% of patients at week 16, 88.46% at week 52, 86.67% at week 104, and 85.71% at week 156. Only two patients discontinued biologics due to complete remission, and mild AEs were reported by four patients. Our findings show that biologics are effective and well tolerated for treating very severe psoriasis, maintaining long-term effectiveness.
Reference44 articles.
1. Effectiveness and safety of anti-IL-23 and anti-IL-17 biological therapies for psoriasis in elderly patients: Real-world experience from two Italian hospitals;Fiorillo;J. Eur. Acad. Dermatol. Venereol.,2023
2. Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment;Mastorino;J. Dtsch. Dermatol. Ges.,2023
3. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review;Armstrong;JAMA,2020
4. Raudonis, T., Gliebute, A., Grigaityte, A.G., Lukosiunaite, Z., Karmaziene, T., and Grigaitiene, J. (2020). A Six-Year Analysis of Biological Therapy for Severe Psoriasis in a Lithuanian Reference Centre of Dermatovenereology. Medicina, 56.
5. Hägg, D., Eriksson, M., Sundström, A., and Schmitt-Egenolf, M. (2013). The higher proportion of men with psoriasis treated with biologics may be explained by more severe disease in men. PLoS ONE, 8.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献